EWTX
NASDAQ HealthcareEdgewise Therapeutics, Inc. - Common Stock
Biotechnology
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
�� 市场数据
| 价格 | $34.43 |
|---|---|
| 成交量 | 796,526 |
| 市值 | 3.69B |
| 贝塔系数 | 0.250 |
| RSI（14日） | 67.4 |
| 200日均线 | $21.69 |
| 50日均线 | $30.72 |
| 52周最高 | $35.00 |
| 52周最低 | $12.15 |
| Forward P/E | -14.71 |
| Price / Book | 7.01 |
🎯 投资策略评分
EWTX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🐋 Institutional Whale (53/100) — 此策略 大盘、机构级别股票.
评分最低的策略： 🔪 Falling Knife (12/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 EWTX in your text
粘贴任何文章、记录或帖子 — 工具将提取 EWTX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.